MarketScreener Homepage > Equities > Nasdaq > Incyte Corporation INCY

Report

Delayed Nasdaq - 01/21 04:00:00 pm
93.9	USD		-2.56%

01/21

INCYTE : Study of Squamous Cell Carcinoma of Anal Canal Accepted for Priority Review at FDA

01/21

INCYTE : Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

01/19

INCYTE : to Report Fourth Quarter and Year-End 2020 Financial Results

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/14/2021	01/15/2021	01/19/2021	01/20/2021	01/21/2021	Date
92.04(c)	90.56(c)	93.96(c)	96.37(c)	93.9(c)	Last
1 143 434	930 173	995 950	937 022	1 175 144	Volume
-0.75%	-1.61%	+3.75%	+2.56%	-2.56%	Change

More quotes

Financials (USD)

Sales 2020	2 530 M - -
Net income 2020	-334 M - -
Net cash position 2020	1 843 M - -
P/E ratio 2020	-62,0x
Yield 2020	-

Sales 2021	2 868 M - -
Net income 2021	576 M - -
Net cash position 2021	2 490 M - -
P/E ratio 2021	36,0x
Yield 2021	-

Capitalization	20 564 M 20 564 M -
EV / Sales 2020	7,40x
EV / Sales 2021	6,30x
Nbr of Employees	1 456
Free-Float	98,6%

More Financials

Company

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and cooperation agreements (3.6%).

Sector

Biotechnology & Medical Research

Calendar

02/18

Earnings Release

More about the company

Notations Surperformance© of Incyte Corporation

Trading Rating :

Investor Rating :

More Ratings

All news about INCYTE CORPORATION

01/21	INCYTE : Study of Squamous Cell Carcinoma of Anal Canal Accepted for Priority Re..	MT
01/21	INCYTE : Announces Acceptance and Priority Review of BLA for Retifanlimab as a P..	BU
01/19	INCYTE : to Report Fourth Quarter and Year-End 2020 Financial Results	BU
01/13	BRIACELL THERAPEUTICS : Announces Presentation at the 2021 Keystone Symposia Con..	AQ
01/12	MORPHOSYS : Incyte New Drug Application for Potential Lymphoma Treatment Accepte..	MT
01/12	PRESS RELEASE : MorphoSys and Incyte Announce -2-	DJ
01/12	INCYTE : and MorphoSys Announce Acceptance by Health Canada of the New Drug Subm..	AQ
01/08	Stocks Close at Fresh Highs as Biden Promises 'Trillions of Dollars' in Stimu..	MT
01/07	RBC Capital Raises Price Targets on Seven Stocks, Lowers Targets on Four, Ahe..	MT
01/06	INCYTE : MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketin..	AQ
01/05	MORPHOSYS : Swissmedic Accepts MorphoSys-Incyte Application for B-Cell Lymphoma ..	MT
01/05	Swiss Regulator Accepts MorphoSys, Incyte's Marketing Application for Lymphom..	MT
01/05	PRESS RELEASE : MorphoSys and Incyte Announce the -2-	DJ
01/05	PRESS RELEASE : MorphoSys and Incyte Announce the Acceptance of the Swissmedic M..	DJ
01/04	INCYTE CORPORATION : Report	CO

More news

News in other languages on INCYTE CORPORATION

01/13	AKTIE IM FOKUS : Morphosys erholt vom Vortagsminus - Zulassung in Kanada
01/12	MORPHOSYS : Health Canada nimmt Tafasitamab-Antrag von Morphosys und Incyte an
2020	Aktien New York Schluss: Dow geht Puste aus nach Rekord - Nasdaq steigt
2020	Aktien New York: Dow geht nach Rekordhoch die Puste aus - Nasdaq stark
2020	Novartis essuie un revers avec le ruxolitinib contre la Covid-19

More news

Analyst Recommendations on INCYTE CORPORATION

2020	RBC Capital Adjusts Incyte PT to $87 From $86, Maintains Sector Perform Ratin..	MT
2020	Morgan Stanley Adjusts Incyte to $97 From $103, Maintains Equal Weight Rating	MT
2020	Oppenheimer Adjusts Incyte's Price Target to $110 From $121, Maintains Outper..	MT

More recommendations

Provided by Scoopnest.com

Chart INCYTE CORPORATION

Duration : Period :

Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | MarketScreener

Full-screen chart

Technical analysis trends INCYTE CORPORATION

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	20
Average target price	107,06 $
Last Close Price	93,90 $
Spread / Highest target	41,6%
Spread / Average Target	14,0%
Spread / Lowest Target	-5,22%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Hervé Hoppenot	Chairman, President & Chief Executive Officer
Christiana Stamoulis	Chief Financial Officer & Executive Vice President
Steven H. Stein	Chief Medical Officer & Executive Vice President
Dashyant Dhanak	Chief Scientific Officer & Executive VP
Paul A. Friedman	Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

INCYTE CORPORATION	10.80%	20 564



MODERNA, INC.	27.29%	49 519
LONZA GROUP AG	4.32%	49 499
CELLTRION, INC.	-13.09%	38 562
IQVIA HOLDINGS INC.	4.76%	36 531
SEAGEN INC.	6.08%	34 515

More Results